Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Relistor

dengue fever mosquito

Takeda dengue vaccine data looks good as it chases Sanofi

TAK-003 achieved a 71% reduction in developing the virus compared to placebo

- PMLiVE

Takeda can’t sway NICE on oral myeloma therapy Ninlaro

Drug not recommended for NHS use in England and Wales

- PMLiVE

NICE reverses stance on Takeda’s Adcetris

But firm criticises final draft guidance's new restrictions on the non-Hodgkin’s lymphoma drug

- PMLiVE

Samsung deal with Takeda looks beyond biosimilars

The duo plan to develop “multiple novel biologic therapies”

- PMLiVE

Takeda unveil final chapters of first graphic novel The Unbeatables

Partners with Marvel to complete the graphic novel as a part of its IBD Unmasked initiative

- PMLiVE

Takeda’s gamble on Ariad pays off with Alunbrig approval

ALK-inhibitor will treat NSCLC patients as second-line therapy

Takeda pilots Apple Watch depression app

Partners with Cognition Kit on patient monitoring wearable

- PMLiVE

Stada opens books to let formal bidding commence

Cinven, Advent International and Bain Capital now have opportunity to revise their bids

- PMLiVE

Advent tops Cinven offer for Stada as third suitor looms

Values the OTC and generics specialist at €3.6bn, with offer open until 27 February

- PMLiVE

TiGenix cell therapy for Crohn’s fistulas shows long-term benefit

Phase III data for the Takeda-partnered drug raises hopes for upcoming EU approval

- PMLiVE

FDA OKs Valeant’s psoriasis drug Siliq, with black box warning

Suicidal ideation labelling adds to challenge in rivalling Novartis’ Cosentyx and Lilly’s Taltz

- PMLiVE

Allergan adds Zeltiq to M&A roster in $2.48n deal

Expands aesthetic pharma business with “best-in-class” body contouring system

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links